175 related articles for article (PubMed ID: 36596435)
1. An experimental and theoretical approach to understand the interaction between particles and mucosal tissues.
Arzi RS; Davidovich-Pinhas M; Cohen N; Sosnik A
Acta Biomater; 2023 Mar; 158():449-462. PubMed ID: 36596435
[TBL] [Abstract][Full Text] [Related]
2. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.
Henry CE; Wang YY; Yang Q; Hoang T; Chattopadhyay S; Hoen T; Ensign LM; Nunn KL; Schroeder H; McCallen J; Moench T; Cone R; Roffler SR; Lai SK
Acta Biomater; 2016 Oct; 43():61-70. PubMed ID: 27424083
[TBL] [Abstract][Full Text] [Related]
3. Mucus barrier-triggered disassembly of siRNA nanocarriers.
Thomsen TB; Li L; Howard KA
Nanoscale; 2014 Nov; 6(21):12547-54. PubMed ID: 25179224
[TBL] [Abstract][Full Text] [Related]
4. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
Foffi G; Pastore A; Piazza F; Temussi PA
Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination.
Augustine R; Ashkenazi DL; Arzi RS; Zlobin V; Shofti R; Sosnik A
Acta Biomater; 2018 Jul; 74():344-359. PubMed ID: 29723705
[TBL] [Abstract][Full Text] [Related]
6. Molecular and cellular cues governing nanomaterial-mucosae interactions: from nanomedicine to nanotoxicology.
das Neves J; Sverdlov Arzi R; Sosnik A
Chem Soc Rev; 2020 Jul; 49(14):5058-5100. PubMed ID: 32538405
[TBL] [Abstract][Full Text] [Related]
7. Mucus-Mimicking Mucin-Based Hydrogels by Tandem Chemical and Physical Crosslinking.
Porfiryeva NN; Zlotver I; Davidovich-Pinhas M; Sosnik A
Macromol Biosci; 2024 Mar; ():e2400028. PubMed ID: 38511568
[TBL] [Abstract][Full Text] [Related]
8. Lipid-based mucus penetrating nanoparticles and their biophysical interactions with pulmonary mucus layer.
Alp G; Aydogan N
Eur J Pharm Biopharm; 2020 Apr; 149():45-57. PubMed ID: 32014491
[TBL] [Abstract][Full Text] [Related]
9. Disruption of the mucus barrier by topically applied exogenous particles.
McGill SL; Smyth HD
Mol Pharm; 2010 Dec; 7(6):2280-8. PubMed ID: 20919744
[TBL] [Abstract][Full Text] [Related]
10. Technological strategies to estimate and control diffusive passage times through the mucus barrier in mucosal drug delivery.
Newby JM; Seim I; Lysy M; Ling Y; Huckaby J; Lai SK; Forest MG
Adv Drug Deliv Rev; 2018 Jan; 124():64-81. PubMed ID: 29246855
[TBL] [Abstract][Full Text] [Related]
11. Food-grade TiO
Talbot P; Radziwill-Bienkowska JM; Kamphuis JBJ; Steenkeste K; Bettini S; Robert V; Noordine ML; Mayeur C; Gaultier E; Langella P; Robbe-Masselot C; Houdeau E; Thomas M; Mercier-Bonin M
J Nanobiotechnology; 2018 Jun; 16(1):53. PubMed ID: 29921300
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle diffusion within intestinal mucus: Three-dimensional response analysis dissecting the impact of particle surface charge, size and heterogeneity across polyelectrolyte, pegylated and viral particles.
Abdulkarim M; Agulló N; Cattoz B; Griffiths P; Bernkop-Schnürch A; Borros SG; Gumbleton M
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):230-8. PubMed ID: 25661585
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronic Acid Molecular Weight-Dependent Modulation of Mucin Nanostructure for Potential Mucosal Therapeutic Applications.
Hansen IM; Ebbesen MF; Kaspersen L; Thomsen T; Bienk K; Cai Y; Malle BM; Howard KA
Mol Pharm; 2017 Jul; 14(7):2359-2367. PubMed ID: 28499338
[TBL] [Abstract][Full Text] [Related]
14. Disassembling the complexity of mucus barriers to develop a fast screening tool for early drug discovery.
Pacheco DP; Butnarasu CS; Briatico Vangosa F; Pastorino L; Visai L; Visentin S; Petrini P
J Mater Chem B; 2019 Aug; 7(32):4940-4952. PubMed ID: 31411620
[TBL] [Abstract][Full Text] [Related]
15. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.
Lai SK; Wang YY; Hanes J
Adv Drug Deliv Rev; 2009 Feb; 61(2):158-71. PubMed ID: 19133304
[TBL] [Abstract][Full Text] [Related]
16. "Mucus-on-Chip": A new tool to study the dynamic penetration of nanoparticulate drug carriers into mucus.
Jia Z; Guo Z; Yang CT; Prestidge C; Thierry B
Int J Pharm; 2021 Apr; 598():120391. PubMed ID: 33621642
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine A Nanosuspensions for Ophthalmic Delivery: A Comparative Study between Cationic Nanoparticles and Drug-Core Mucus Penetrating Nanoparticles.
Yan R; Xu L; Wang Q; Wu Z; Zhang H; Gan L
Mol Pharm; 2021 Dec; 18(12):4290-4298. PubMed ID: 34731571
[TBL] [Abstract][Full Text] [Related]
18. Mucus as a barrier to drug delivery – understanding and mimicking the barrier properties.
Boegh M; Nielsen HM
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):179-86. PubMed ID: 25349046
[TBL] [Abstract][Full Text] [Related]
19. Mucus models to evaluate the diffusion of drugs and particles.
Lock JY; Carlson TL; Carrier RL
Adv Drug Deliv Rev; 2018 Jan; 124():34-49. PubMed ID: 29117512
[TBL] [Abstract][Full Text] [Related]
20. Mucus permeating thiomer nanoparticles.
Köllner S; Dünnhaupt S; Waldner C; Hauptstein S; Pereira de Sousa I; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):265-72. PubMed ID: 25603199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
